Who is sponsoring NCT02922907?

NCT02922907 is sponsored by University of Southern California.

What drugs are being tested in NCT02922907?

Interventions in NCT02922907: arabinoxylan rice bran, Placebo for arabinoxylan rice bran.

What condition does NCT02922907 study?

NCT02922907 studies Inflammation in HIV Infection.

Is NCT02922907 still recruiting?

NCT02922907 is currently completed. Last updated 29 April 2021.

Last reviewed 2021-04-29 · How we verify

NCT02922907: BRM4

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rice Bran Supplementation in Treated HIV Infection

Completed NA Last updated 29 April 2021

What this trial tests

NA trial testing arabinoxylan rice bran in Inflammation in HIV Infection in 24 participants. Completed in 3 December 2019.

Timeline

24 March 2017

Primary endpoint
3 December 2018

3 December 2019

Quick facts

Lead sponsor	University of Southern California
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	24
Start date	24 March 2017
Primary completion	3 December 2018
Estimated completion	3 December 2019
Sites	1 location across United States

Drugs / interventions tested

arabinoxylan rice bran
Placebo for arabinoxylan rice bran

Conditions studied

Inflammation in HIV Infection — all drugs for Inflammation in HIV Infection →

Sponsor

University of Southern California

Who can join

18 and older, any sex, with Inflammation in HIV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Double-blind placebo-controlled randomized trial of Arabinoxylan Rice Bran Supplementation for 12 weeks with BRM4 in HIV-infected participants with inadequate immune reconstitution.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Southern California trials

Trials by the same sponsor.

NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia · NA · not yet recruiting
NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration · NA · not yet recruiting
NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management · NA · withdrawn
NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02922907 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Southern California
Last refreshed: 29 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02922907.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing